Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
Baxter
AstraZeneca
US Department of Justice
Argus Health
Daiichi Sankyo
McKesson
Novartis
Accenture

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,358,240

« Back to Dashboard

Which drugs does patent 9,358,240 protect, and when does it expire?

Patent 9,358,240 protects TYVASO and is included in one NDA.

This patent has ten patent family members in six countries.
Summary for Patent: 9,358,240
Title:Treprostinil administration by inhalation
Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Inventor(s): Olschewski; Horst (Graz, AT), Roscigno; Robert (Chapel Hill, NC), Rubin; Lewis J. (LaJolla, CA), Schmehl; Thomas (Giessen, DE), Seeger; Werner (Giessen, DE), Sterritt; Carl (Weybridge, GB), Voswinckel; Robert (Giessen, DE)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:12/591,200
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 9,358,240

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap TYVASO treprostinil SOLUTION;INHALATION 022387-001 Jul 30, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,358,240

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,339,507 Treprostinil administration by inhalation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,358,240

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101390579 ➤ Subscribe
South Korea 20090007797 ➤ Subscribe
Japan 2016006066 ➤ Subscribe
Japan 2014114269 ➤ Subscribe
Japan 5797376 ➤ Subscribe
Japan 2009537246 ➤ Subscribe
European Patent Office 2026816 ➤ Subscribe
China 101495122 ➤ Subscribe
Canada 2654492 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2007134292 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Accenture
Julphar
Fish and Richardson
Covington
Deloitte
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot